# US 2024/0197658 A1 · Composition for inhibiting anti-cancer drug resistance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197658 A1
- Document ID: US20240197658A1
- Status: Published application
- Kind: A1
- Application number: 18/531,132
- Filed: 2023-12-06
- Published: 2024-06-20
- Earliest claimed: 2022-12-09
- Assignees: Ajou University Industry-Academic Cooperation Foundation
- Applicants: Ajou University Industry-Academic Cooperation Foundation
- Inventors: Hoon HUR; In-Hye Ham
- Web page: https://patentgrep.com/patent/US20240197658A1

## CPC

- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61P 35/00: Antineoplastic agents
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a composition for inhibiting anti-cancer drug resistance comprising a compound represented by Chemical Formula 1 below as an active ingredient: (wherein, R1 and R2 are each independently hydrogen, substitutable linear or branched C1-C12 alkyl, substitutable C3-C12 cycloalkyl, or substitutable C6-C18 aryl, R3 is carboxyl, hydroxyl, or acetyl, and the substitution is performed by oxygen, nitrogen, sulfur, linear or branched C1-C6 alkyl, C6-C20 aryl, halogen, or a combination thereof).

## Claims

### Claim 1

A composition for inhibiting anti-cancer drug resistance comprising a compound represented by Chemical Formula 1 below as an active ingredient:
(wherein,
R1 and R2 are each independently hydrogen, substitutable linear or branched C1-C12 alkyl, substitutable C3-C12 cycloalkyl, or substitutable C6-C18 aryl,
R3 is carboxyl, hydroxyl, or acetyl, and
the substitution is performed by oxygen, nitrogen, sulfur, linear or branched C1-C6 alkyl, C6-C20 aryl, halogen, or a combination thereof).

### Claim 2 (depends on 1)

The composition for inhibiting anti-cancer drug resistance of claim 1, wherein the compound represented by Chemical Formula 1 above comprises a compound represented by Chemical Formula 2 below:
(wherein,
R1 and R2 are each independently hydrogen, substitutable linear or branched C1-C12 alkyl, substitutable C3-C12 cycloalkyl, or substitutable C6-C18 aryl,
R3 is carboxyl, hydroxyl, or acetyl, and
the substitution is performed by oxygen, nitrogen, sulfur, linear or branched C1-C6 alkyl, C6-C20 aryl, halogen, or a combination thereof).

### Claim 3 (depends on 2)

The composition for inhibiting anti-cancer drug resistance of claim 2, wherein the compound represented by Chemical Formula 2 above comprises the following compound:

### Claim 4 (depends on 1)

The composition for inhibiting anti-cancer drug resistance of claim 1, wherein the compound represented by Chemical Formula 1 above inhibits senescence caused by an anti-cancer drug occurring in cancer-associated fibroblasts (CAFs) formed around cancer cells.

### Claim 5 (depends on 4)

The composition for inhibiting anti-cancer drug resistance of claim 4, wherein the cancer is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, breast cancer, melanoma, thyroid cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, renal cell cancer, metastatic cancer, prostate cancer, lung cancer and combinations thereof.

### Claim 6 (depends on 5)

The composition for inhibiting anti-cancer drug resistance of claim 5, wherein the cancer is gastric cancer.

### Claim 7 (depends on 1)

The composition for inhibiting anti-cancer drug resistance of claim 1, wherein the anti-cancer drug is selected from the group consisting of 5-fluorouracil (5-FU), dacomitinib, osimertinib, cetuximab, Pyrotinib, Lcotinib, panitumumab, zalutumumab, Nimotuzumab, matuzumab, gefitinib, erlotinib, Lapatinib, neratinib, Vandetanib, necitumumab, afatinib, Taxol, Cisplatin, doxorubicin, paclitaxel, vincristine, topotecan, docetaxel, gleevec, carboplatin, daunorubicin, valrubicin, flutamide, gemcitabine, Etoposide and combinations thereof.

### Claim 8 (depends on 1)

A pharmaceutical composition for preventing or treating cancer comprising the composition for inhibiting anti-cancer drug resistance according to claim 1.

### Claim 9 (depends on 8)

The pharmaceutical composition for preventing or treating cancer of claim 8, wherein the cancer is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, breast cancer, melanoma, thyroid cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, renal cell cancer, metastatic cancer, prostate cancer, lung cancer and combinations thereof.

### Claim 10 (depends on 9)

The pharmaceutical composition for preventing or treating cancer of claim 9, wherein the cancer is gastric cancer.
